% | $
Quotes you view appear here for quick access.

Johnson & Johnson Message Board

  • credorules credorules Oct 1, 2003 8:57 AM Flag

    New competition for DE stents heats up

    Seems like there is a new player in the treatment for restenosis.
    If there is a strong potential that this new drug could be an alternative to DE stents, J&J should consider an acquisition.

    "AVI BioPharma has reported positive clinical trial results involving its drug therapy for cardiovascular restenosis. The multicenter clinical trial evaluated the safety and effectiveness of Resten-NG in patients at high risk of cardiovascular restenosis following angioplasty and stent placement. Resten-NG inhibits the expression of the c-myc gene, which plays a key role in the development of the pathology leading to restenosis. Fifty-seven patients were enrolled in the trial and randomized into three groups: a control arm, a subtherapeutic dose (3 mg) treatment arm, and a therapeutic dose (10 mg) treatment arm. Patients in the therapeutic dose and subtherapeutic dose treatment arms received the drug via a coronary delivery catheter directly to the site of angioplasty and stent placement. The primary efficacy endpoint was angiographic analysis at six months. The restenosis rate was 33.3 percent in both the control and subtherapeutic dose treatment arms, and 8.3 percent in the therapeutic dose treatment arm, according to the company."

115.70+1.14(+1.00%)Oct 27 4:00 PMEDT